COMPOSITION:

Each film-coated tablet contains Pirtobrutinib .................................. 50 mg.

INDICATION:  

LuciPirto is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.  

DOSAGE AND USE:

The recommended dosage of LuciPirto is 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets.  

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciPirto during Pregnancy and Lactation.